Effects of antipsychotic drugs on Ito, INa, I sus, IK1, and hERG: QT prolongation, structure activity relationship, and network analysis

Pharmaceutical Research

Volumn 23, Issue 6, 2006, Pages 1133-1143

  Crumb Jr , William J ^a   Ekins, Sean ^b,c,d   Sarazan, R Dustan ^b,e   Wikel, James H ^b,f   Wrighton, Steven A ^b   Carlson, Christopher ^b   Beasley Jr , Charles M ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c GeneGo bioinformatics software Inc   (United States)

^d GeneGo Inc   (United States)

^e 206 Carnegie Center   (United States)

^f Coalesix Inc ^*  (United States)

Author keywords

Antipsychotics; Cardiac ion channels; hERG; QT

Indexed keywords

2 HYDROXYOLANZAPINE; CLOZAPINE; CLOZAPINE N OXIDE; DRUG METABOLITE; HALOPERIDOL; ION CHANNEL; MESORIDAZINE; NEUROLEPTIC AGENT; NORCLOZAPINE; NOROLANZAPINE; OLANZAPINE; PALIPERIDONE; PIMOZIDE; POTASSIUM CHANNEL HERG; RISPERIDONE; SERTINDOLE; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ACTION POTENTIAL; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; DEVICE; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHOBICITY; IC 50; ION CURRENT; MODEL; MOLECULAR MODEL; PATCH CLAMP; PRIORITY JOURNAL; QT PROLONGATION; STRUCTURE ACTIVITY RELATION;

ACTION POTENTIALS; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CELL LINE; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; IMIDAZOLES; INDOLES; ION CHANNELS; MIDDLE AGED; MOLECULAR STRUCTURE; MYOCYTES, CARDIAC; NEURAL NETWORKS (COMPUTER); POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; SODIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP; THIORIDAZINE; TRANSFECTION;

EID: 33745399855     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-0070-7     Document Type: Article

References (48)

1. S. H. Thomas 1994 Drugs, QT interval abnormalities and ventricular arrhythmias Adverse Drug React. Toxicol. Rev. 13 77 102
2. D. M. Barry H. Xu R. B. Schuessler J. M. Nerbonne 1998 Functional knockout of the transient outward current, long-QT syndrome, and cardiac remodeling in mice expressing a dominant-negative Kv4 alpha subunit Circ. Res. 83 560 567
3. M. C. Trudeau J. W. Warmke B. Ganetzky G. A. Robertson 1995 HERG, a human inward rectifier in the voltage-gated potassium channel family Science 269 92 95
4. J. W. Warmke B. Ganetzky 1994 A family of potassium channel genes related to eag in Drosophila and mammals Proc. Natl. Acad. Sci. USA 91 3438 3442
5. Kr potassium channel Cell 81 299 307
6. M. E. Curran I. Splawski K. W. Timothy G. M. Vincent E. D. Green M. T. Keating 1995 A molecular basis for the cardiac arrhythmia: HERG mutations cause long QT syndrome Cell 80 795 803
7. H. Suessbrich R. Schonherr S. H. Heinemann B. Attali F. Lang A. E. Busch 1997 The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes Br. J. Pharmacol. 120 968 974
8. A. Jeron G. F. Mitchell J. Zhou M. Murata B. London P. Buckett S. D. Wiviott G. Koren 2000 Inducible polymorphic ventricular tachyarrhythmias in a transgenic mouse model with a long Q-T phenotype Am. J. Physiol. Heart Circ. Physiol. 278 H1891 H1898
9. R. Welchand P. Chue 2000 Antipsychotic agents and QT changes J. Psychiatry Neurosci. 25 154 160
10. D. Mehta S. Mehta J. Petit W. Shriner 1979 Cardiac arrhythmia and haloperidol Am. J. Psychiatr. 136 1468 1469
11. S. Ekins W. J. Crumb R. D. Sarazan J. H. Wikel S. A. Wrighton 2002 Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel J. Pharmacol. Exp. Ther. 301 427 434
12. W. J. Crumb Jr. J. D. Pigott C. W. Clarkson 1995 Comparison of Ito in young and adult human atrial myocytes: evidence for developmental changes Am. J. Physiol. 268 H1335 H1342
13. O. P. Hamill A. Marty E. Neher B. Sakmann F. J. Sigworth 1981 Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches Pflugers Arch. 391 85 100
14. S. Ekins A. Bugrim Y. Nikolsky T. Nikolskaya 2005 Systems biology: applications in drug discovery S. C. Gad Drug Discovery Handbook Wiley New York 123 183
15. S. Ekins E. Kirillov E. A. Rakhmatulin T. Nikolskaya 2005 A Novel Method for Visualizing Nuclear Hormone Receptor Networks Relevant to Drug Metabolism Drug Metab. Dispos. 33 474 481
16. E. P. Harrigan J. J. Miceli R. Anziano E. Watsky K. R. Reeves N. R. Cutler J. Sramek T. Shiovitz M. Middle 2004 A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition J. Clin. Psychopharmacol. 24 62 69
17. Pfizer briefing document for Zeldox Capsules (Ziprasidone HCl). July 19, 2000.
18. K. Titier M. Canal E. Deridet A. Abouelfath S. Gromb M. Molimard N. Moore 2004 Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice Toxicol. Appl. Pharmacol. 199 52 60
19. M. Malik 2001 Problems of heart rate correction in assessment of drug-induced QT interval prolongation J. Cardiovasc. Electrophysiol. 12 411 420
20. M. Malik A. J. Camm 2001 Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling Drug Safety 24 323 351
21. R. R. Shah 2002 The significance of QT interval in drug development Br. J. Clin. Pharmacol. 54 188 202
22. H. J. Witchel J. C. Hancox D. J. Nutt 2003 Psychotropic drugs, cardiac arrhythmia, and sudden death J. Clin. Psychopharmacol. 23 58 77
23. R. Webster D. Leishman D. Walker 2002 Towards a drug concentration effect relationship for QT prolongation and torsades de pointes Curr. Opin. Drug Discov. Dev. 5 116 126
24. W. Crumband I. Cavero 1999 QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development PSST 2 270 280
25. S. Zhang Z. Zhou Q. Gong J. C. Makielski C. T. January 1999 Mechanism of block and identification of the verapamil binding domain to HERG potassium channels Circ. Res. 84 989 998
26. J. Kang X. L. Chen H. Wang J. Ji W. Reynolds S. Lim J. Hendrix D. Rampe 2004 Cardiac ion channel effects of tolterodine J. Pharmacol. Exp. Ther. 308 935 940
27. M. B. Thomsen P. G. Volders M. Stengl R. L. Spatjens J. D. Beekman U. Bischoff M. A. Kall K. Frederiksen J. Matz M. A. Vos 2003 Electrophysiological safety of sertindole in dogs with normal and remodeled hearts J. Pharmacol. Exp. Ther. 307 776 784
28. F. M. Belpaire F. A. Vanderheeren M. G. Bogaert 1975 Binding of thioridazine and some of its metabolites to human serum protein and human albumin Arzneim. Forsch. 25 1969 1971
29. J. T. Niemann J. S. Stapczynski R. J. Rothstein M. M. Laks 1981 Cardiac conduction and rhythm disturbances following suicidal ingestion of mesoridazine Ann. Emerg. Med. 10 585 588
30. S. A. Fayer 1986 Torsades de pointes ventricular tachyarrhythmia associated with haloperidol J. Clin. Psychopharmacol. 6 375 376
31. I. Paakkari 2002 Cardiotoxicity of new antihistamines and cisapride Toxicol. Lett. 127 279 284
32. H. A. Nasrallah 1978 Factors influencing phenothiazine-induced ECG changes Am. J. Psychiatr. 135 118 119
33. N. A. Aunsholt 1989 Prolonged Q-T interval and hypokalemia caused by haloperidol Acta Psychiatr. Scand. 79 411 412
34. M. N. Siddiqui H. Zafar R. Alvi M. Ahmed 1998 Hypomagnesaemia in postoperative patients: an important contributing factor in postoperative mortality Int. J. Clin. Pract. 52 265 267
35. S. Ekins P. W. Swaan 2004 Development of computational models for enzymes, transporters, channels and receptors relevant to ADME/TOX Rev. Comp. Chem. 20 333 415
36. J. S. Mitcheson J. Chen M. Lin C. Culberson M. C. Sanguinetti 2000 A structural basis for drug-induced long QT syndrome Proc. Natl. Acad. Sci. U. S. A. 97 12329 12333
37. S. Ekins 2004 Predicting undesirable drug interactions with promiscuous proteins in silico Drug Discov. Today 9 276 285
38. H. Li J. Sutter R. Hoffman 2000 HypoGen: an automated system for generating 3D predictive pharmacophore models O. F. Guner Pharmacophore Perception, Development, and Use in Drug Design IUL San Diego 173 189
39. J. S. Mitcheson 2003 Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine Br. J. Pharmacol. 139 883 884
40. I. Huys C. Q. Xu C. Z. Wang H. Vacher M. F. Martin-Eauclaire C. W. Chi J. Tytgat 2004 BmTx3, a scorpion toxin with two putative functional faces separately active on A-type K+ and HERG currents Biochem. J. 378 745 752
41. Y. V. Korolkova E. V. Bocharov K. Angelo I. V. Maslennikov O. V. Grinenko A. V. Lipkin E. D. Nosyreva K. A. Pluzhnikov S. P. Olesen A. S. Areseniev E. V. Grishin 2002 New binding site on common molecular scaffold provides HERG channel specificity of scorpion toxin BeKm-1 J. Biol. Chem. 277 43104 43109
42. A. M. Torres P. Bansal P. F. Alewood J. A. Bursill P. W. Kuchel J. I. Vandenberg 2003 Solution structure of CnErg1 (Ergtoxin), a HERG specific scorpion toxin FEBS Lett. 539 138 142
43. S. Ekins 2004 Predicting undesirable drug interactions with promiscuous proteins in silico Drug Discov. Today 9 276 285
44. A. De Luca S. Talon M. De Bellis J. F. Desaphy G. Lentini F. Corbo A. Scilimati C. Franchini V. Tortorella D. C. Camerino 2003 Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds Mol. Pharmacol. 64 932 945
45. L. S. Goodman L. E. Limbard P. B. Molinoff R. W. Ruddon A. G. Gilman 2003 Goodman & Gilman's the Pharmacological Basis of Therapeutics McGraw-Hill New York
46. Physicians' Desk Reference (PDR), Medical Economics, Thompson Healthcare, Montvale, NJ, 2004.
47. E. C. Dinovo H. Pollak L. A. Gottschalk 1984 Partitioning of thioridazine and mesoridazine in human blood fractions Methods Find. Exp. Clin. Pharmacol. 6 143 146
48. G. Nyberg R. Axelsson E. Martensson 1978 Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients Eur. J. Clin. Pharmacol. 14 341 350